Dolutegravir monotherapy as maintenance ART bites the dust

Affiliations

¹ Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia; Clinical AIDS Research and Education Center, University of California Los Angeles, LA, USA.
² Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia. Electronic address: jennifer.hoy@monash.edu.

Comment

Janine M Trevillyan et al. Lancet HIV. 2017 Dec.

. 2017 Dec;4(12):e531-e532.

doi: 10.1016/S2352-3018(17)30168-6. Epub 2017 Oct 26.

¹ Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia; Clinical AIDS Research and Education Center, University of California Los Angeles, LA, USA.
² Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia. Electronic address: jennifer.hoy@monash.edu.

No abstract available

Comment on

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, Schurink C, Bax H, Derksen M, Andrinopoulou ER, van der Ende M, van Gorp E, Nouwen J, Verbon A, Bierman W, Rijnders B. Wijting I, et al. Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26. Lancet HIV. 2017. PMID: 29107562 Clinical Trial.